Press Releases

BRIDGEWATER, N.J., June 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that management will present at the following investor conferences:

• The Nasdaq 38th Investor Conference in London, on Tuesday, June 12, 2018 at 3:30 a.m. ET.
• The Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, on Wednesday, June 13, 2018 at 1:40 p.m. ET.
• The JMP Securities Life Sciences Conference in New York City on Wednesday, June 20, 2018 at 3:00 p.m. ET.

The presentations will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcasts will be archived for a period of 90 days following the conclusion of each live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The Company’s lead product candidate is ALIS, which is in late-state development for adult patients with treatment refractory NTM lung disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal.  Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.  For more information, visit www.insmed.com.

Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
blaine.davis@insmed.com